Biotechnology & Life Sciences Global On demand · 24-48h

Global Point-of-Care Testing Market Strategic Research Report

Global Point-of-Care Testing Market Strategic Research Repor…
$3,500 USD
Market Research Reports
Strategic Research Report
Global Point-of-Care Testing Market
$48.6B2025
7.9%CAGR
2032Forecast
Market Research Reports · Global
Market Research Reports Intelligence Series

By Type: Lateral Flow Assay Devices, Molecular POCT Platforms, Glucose Monitoring

By Application: Infectious Disease Testing, Cardiac Biomarker Testing, Drug & Toxicology Screening

Regional Forecast: Asia Pacific, Latin America, MEA, Europe, North America

Region: Global
Formats: PDF, Excel, Word & PowerPoint
Base year: 2025 · forecast to 2032
Market size 2025
$48.6B
Billion USD
Forecast CAGR
7.9%
2025-2032
Forecast 2032
$82.8B
Projected
영역들
5
Asia Pacific · Latin America · MEA · Europe · North America

개요

The global point-of-care testing (POCT) market has emerged as one of the most strategically consequential segments within in-vitro diagnostics, underpinned by the fundamental shift in healthcare delivery toward decentralized, rapid-result testing. Valued at approximately USD 48.6 billion in 2024, the market encompasses a broad spectrum of diagnostic modalities—from lateral flow immunoassays and molecular POCT platforms to glucose monitoring systems and blood gas analyzers—deployed across hospital emergency departments, physician offices, pharmacies, and increasingly in patients' homes. The COVID-19 pandemic served as an inflection point that permanently altered procurement behavior, regulatory pathways, and end-user acceptance of decentralized diagnostics, creating a structural demand base that persists well beyond the acute public health emergency.

Market snapshot

Global Point-of-Care Testing Market Strategic Research Report snapshot, 2025–2032

Source: Market Research Reports
Market size CAGR 7.9%
Regional growth momentum
Market share by segment
Key metrics
Base value
$48.6B
2025
Forecast
$82.8B
2032
Volume
42800
Million Dosage Units, 2025
Volume 2032
72877.6
Million Dosage Units
© MarketResearchReports.comDisclaimer: The actual data may vary in the final report which undergoes verification check post order confirmation.

Segments covered in this report

By Type
Lateral Flow Assay DevicesMolecular POCT PlatformsGlucose Monitoring
By Application
Infectious Disease TestingCardiac Biomarker TestingDrug & Toxicology Screening

Table of contents

Click a chapter to expand
01Executive Summary
  • 1.1 Market Synopsis
  • 1.2 Key Findings
  • 1.3 Strategic Recommendations
02Industry Overview & Forecast
  • 2.1 Market Definition & Scope
  • 2.2 Market Value Forecast, 2025-2032 & Volume Forecast (Million Dosage Units)
  • 2.3 CAGR Analysis & Confidence Intervals
  • 2.4 Historical Market Review, 2019-2024
  • 2.5 Scenario Analysis (Base, Bull, Bear Cases)
03Market Segmentation by Type
  • 3.1 Market by Type Overview
  • 3.2 Lateral Flow Assay (LFA) Devices (Value & Volume)
  • 3.3 Molecular Point-of-Care Diagnostics (Value & Volume)
  • 3.4 Glucose & Diabetes Monitoring Devices (Value & Volume)
  • 3.5 Blood Gas & Electrolyte Analyzers (Value & Volume)
  • 3.6 Cardiac Marker Testing Devices (Value & Volume)
  • 3.7 Coagulation Testing Devices (Value & Volume)
04Market Segmentation by Application
  • 4.1 Market by Application Overview
  • 4.2 Infectious Disease Testing (Value & Volume)
  • 4.3 Glucose & Diabetes Management (Value & Volume)
  • 4.4 Cardiac & Metabolic Biomarker Testing (Value & Volume)
  • 4.5 Pregnancy & Fertility Testing (Value & Volume)
  • 4.6 Drug Abuse & Toxicology Screening (Value & Volume)
  • 4.7 Oncology & Cancer Marker Testing (Value & Volume)
05Regional Market Forecast
  • 5.1 Regional Revenue Share & CAGR (2024 vs 2032)
  • 5.2 Asia Pacific (Value & Volume)
  • 5.3 North America (Value & Volume)
  • 5.4 Europe (Value & Volume)
  • 5.5 Middle East & Africa
  • 5.6 Latin America
06Country-Level Market Forecast
  • 6.1 Top Countries Overview
  • 6.2 United States
  • 6.3 China
  • 6.4 Germany
  • 6.5 Japan
  • 6.6 India
  • 6.7 United Kingdom
07Growth Drivers & Inhibitors
  • 7.1 Rising Prevalence of Chronic and Infectious Diseases Driving Continuous Diagnostic Demand
  • 7.2 Expansion of Decentralized and Home-Based Healthcare Models Reducing Lab Dependency
  • 7.3 Regulatory Acceleration of Emergency Use Authorizations and CLIA-Waived Device Approvals
  • 7.4 Market Restraints & Challenges
  • 7.5 Opportunities & White-Space Analysis
08Key Company Profiles
  • 8.1 Abbott Laboratories — Revenue, Strategy, Key Products
  • 8.2 Roche Diagnostics — Revenue, Strategy, Key Products
  • 8.3 Danaher Corporation (Cepheid, Radiometer) — Revenue, Strategy, Key Products
  • 8.4 Siemens Healthineers — Revenue, Strategy, Key Products
  • 8.5 bioMérieux SA — Revenue, Strategy, Key Products
  • 8.6 BD (Becton, Dickinson and Company) — Revenue, Strategy, Key Products
  • 8.7 Quidel Corporation (QuidelOrtho) — Revenue, Strategy, Key Products
  • 8.8 Instrumentation Laboratory (Werfen) — Revenue, Strategy, Key Products
  • 8.9 Trinity Biotech — Revenue, Strategy, Key Products
  • 8.10 SD Biosensor — Revenue, Strategy, Key Products
09Competitive Landscape
  • 9.1 Market Concentration & Competitive Intensity
  • 9.2 Market Share Analysis (2024)
  • 9.3 Competitive Positioning Matrix
  • 9.4 Recent Developments: M&A, Partnerships & Product Launches (2023-2025)
10Porter's Five Forces Analysis
  • 10.1 Threat of New Entrants
  • 10.2 Bargaining Power of Buyers
  • 10.3 Bargaining Power of Suppliers
  • 10.4 Threat of Substitute Products
  • 10.5 Competitive Rivalry Intensity
11PESTLE Analysis
  • 11.1 Political Factors
  • 11.2 Economic Factors
  • 11.3 Social & Demographic Factors
  • 11.4 Technological Factors
  • 11.5 Legal & Regulatory Factors
  • 11.6 Environmental Factors
12SWOT Analysis
  • 12.1 Market-Level Strengths
  • 12.2 Market-Level Weaknesses
  • 12.3 Strategic Opportunities
  • 12.4 External Threats
13Future Trends & Outlook
  • 13.1 Integration of Artificial Intelligence and Machine Learning into POCT Readers for Autonomous Result Interpretation
  • 13.2 Multiplex Microfluidic Cartridge Platforms Enabling Simultaneous Multi-Pathogen Detection at the Point of Care
  • 13.3 Wearable Biosensor Convergence with POCT for Continuous Real-Time Metabolic and Cardiac Monitoring
  • 13.4 Long-Term Market Outlook (2033-2035)
  • 13.5 Investment & M&A Activity Outlook

Frequently asked questions

What is the size of the point-of-care testing market?
The global point-of-care testing market was valued at approximately USD 48.6 billion in 2024 and is projected to reach approximately USD 89.4 billion by 2032. In volume terms, the market processed an estimated 42.8 billion dosage units (individual test consumables) in 2024, reflecting the scale of decentralized diagnostic activity worldwide.
What is the CAGR of the point-of-care testing market?
The global point-of-care testing market is forecast to grow at a compound annual growth rate (CAGR) of approximately 7.9% over the forecast period from 2025 to 2032, driven by structural shifts toward decentralized diagnostics, chronic disease burden, and ongoing technological advancement in rapid testing platforms.
What is driving growth in the point-of-care testing market?
Three primary forces underpin market expansion. First, the escalating global prevalence of chronic conditions such as diabetes, cardiovascular disease, and respiratory illness sustains persistent demand for near-patient testing. Second, healthcare systems across high- and middle-income markets are actively restructuring care delivery toward primary care settings, urgent care centers, and home environments, each requiring reliable rapid diagnostics. Third, regulatory bodies including the U.S. FDA and the European Commission have accelerated approval pathways—particularly CLIA-waived classifications and CE-IVD clearances—that shorten time-to-market for new POCT devices and expand the addressable end-user base.
Who are the leading companies in the point-of-care testing market?
The market is led by a concentrated group of global diagnostics majors. Abbott Laboratories holds a commanding position through its i-STAT and BinaxNOW product lines. Roche Diagnostics competes through its cobas Liat molecular platform and Accu-Chek diabetes portfolio. Danaher Corporation operates in the segment via Cepheid's GeneXpert systems and Radiometer's blood gas analyzers. Siemens Healthineers offers the CLINITEST and RAPIDPoint platforms. QuidelOrtho (formed by the merger of Quidel and Ortho Clinical Diagnostics) is a formidable player in lateral flow and immunoassay-based rapid testing.
Which region dominates the point-of-care testing market?
North America holds the largest revenue share in the global point-of-care testing market, accounting for approximately 38% of total market value in 2024. This leadership reflects the region's high per-capita healthcare expenditure, well-established reimbursement frameworks for POCT under CMS guidelines, extensive urgent care and retail clinic infrastructure, and the outsized demand generated during the COVID-19 pandemic that permanently elevated institutional procurement volumes. Asia Pacific represents the fastest-growing region through the forecast period.
What segments are covered in this report?
The report provides comprehensive segmentation across device type (lateral flow assay devices, molecular POCT platforms, glucose and diabetes monitoring devices, blood gas and electrolyte analyzers, cardiac marker testing devices, and coagulation testing devices), application (infectious disease testing, glucose and diabetes management, cardiac and metabolic biomarker testing, pregnancy and fertility testing, drug abuse and toxicology screening, and oncology marker testing), five global regions, and six key country-level markets.
What is the forecast period covered in this report?
This report covers a forecast period from 2025 to 2032, with 2024 serving as the base year for all market sizing and volume calculations. Historical data covering the period from 2019 to 2024 is also included to contextualize pre- and post-pandemic market trajectories.

Research Methodology

All MarketResearchReports.com strategic research reports follow a rigorous, multi-stage methodology combining AI-assisted data synthesis with expert analyst validation.

01
Secondary Research & Data Aggregation

Systematic collection from 500+ verified sources including SEC filings, industry databases (Bloomberg, Statista, OECD), regulatory filings, trade publications, patent databases, and company annual reports. AI-assisted extraction identifies relevant data points across 10,000+ documents per report.

02
Market Sizing — Bottom-Up & Top-Down

Dual-validation approach: bottom-up sizing aggregates segment-level production, consumption, and trade data; top-down sizing cross-validates against macroeconomic indicators and total addressable market estimates. Discrepancies >5% trigger analyst review.

03
Competitive Intelligence

Company profiles built from public financial disclosures, product launches, M&A activity, job postings (as capability proxies), and supply chain mapping. Market share estimates triangulated across revenue, capacity, and shipment data.

04
Demand Forecasting

CAGR projections use time-series regression on 5-10 years of historical data, adjusted for identified demand drivers (technology adoption curves, regulatory catalysts, demographic shifts) and demand inhibitors (cost barriers, substitution risk). Scenario modeling covers base, optimistic, and conservative cases.

05
Analyst Validation & Quality Assurance

All quantitative outputs reviewed by a domain-specialist analyst before publication. Data triangulation requires minimum 3 independent sources for every key figure. Reports undergo a structured peer review against our 47-point quality checklist covering methodology, data citations, logical consistency, and formatting standards.

06
Continuous Updates

On-demand reports are generated at time of purchase, incorporating the most recent available data. Static reports are republished when underlying market conditions shift by >10% from baseline assumptions. Purchasers receive update notifications for 12 months.

All data sources are cited within the report. View our full research methodology →
Select a license
from US$3,500.00
Report License Type
Optional add-ons
On demand · delivered within 24-48 hours
Secure checkout · SSL encrypted
License terms included
Post-purchase analyst support
Custom research

Need a customized version?

Get country-, segment- or company-specific intelligence tailored to your exact requirements.

Request custom research →
Talk to a research advisor USA: +1-302-703-9904 India: +91-8762746600
Trusted by

Leading Brands in This Industry

Logos are trademarks of their respective owners and indicate a verified past business relationship, not a current partnership or endorsement.